Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
50%(5 trials)

Phase Distribution

Ph phase_3
6
55%
Ph not_applicable
1
9%
Ph phase_2
2
18%
Ph phase_4
2
18%

Phase Distribution

0

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
6(54.5%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Other(1)

Detailed Status

Completed10
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (18.2%)
Phase 36 (54.5%)
Phase 42 (18.2%)
N/A1 (9.1%)

Trials by Status

unknown19%
completed1091%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863
completedphase_3

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00501293
completedphase_3

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

NCT00151957
completedphase_2

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

NCT00151970
completedphase_3

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00499863Phase 3

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Completed
NCT00501293Phase 3

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Completed
NCT00151957Phase 3

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

Completed
NCT00151970Phase 2

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Completed
NCT00151983Phase 3

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Completed
NCT00466791Phase 2

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Completed
NCT00444574Phase 3

Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Completed
NCT00541346Phase 3

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Completed
NCT00889915Phase 4

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

Completed
NCT00586157Phase 4

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Completed
NCT00572026Not Applicable

Enhancing ADHD Driving Performance With Stimulant Medication

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11